CHICAGO & OTTAWA, Ontario–(BUSINESS WIRE)–Cresco Labs Inc. (“Cresco Labs” or the “Company” – CSE:
CL, OTCQX: CRLBF) and CannaRoyalty Corp. d/b/a Origin House (“Origin
House” – CSE: OH, OTCQX: ORHOF) today announced that Charlie
Bachtell, CEO & Co-Founder of Cresco Labs, and Marc Lustig, Chairman &
CEO of Origin House, will be presenting and meeting institutional
investors together at Canaccord Genuity’s 3rd Annual Cannabis
Conference on Tuesday, May 14, 2019 in New York City.
The combined presentation will be available via a live webcast here.
The webcast will be available for 90 days following the presentation.
The Annual Cannabis Conference provides attendees the opportunity to
gain valuable insight into the rapidly-developing cannabis industry from
some of the industry’s leading experts. The full-day event will feature
industry leaders sharing their perspectives on the exciting
opportunities and challenges experienced within the industry.
THE 3RD ANNUAL CANACCORD GENUITY CANNABIS
Date: Tuesday, May 14, 2019
Location: Grand Hyatt New York in New York,
ABOUT CRESCO LABS
Cresco Labs, based in Chicago, is a leading U.S. cannabis company with
experienced management, access to capital and a demonstrated growth
strategy. As a differentiated grower, processor and retailer of premium
cannabis operating across the United States, the company focuses on
entering highly regulated markets with outsized demand potential and
strong regulatory structures. Its impressive speed-to-market gives
Cresco a distinct competitive advantage as it replicates its model to
expand its national footprint. Cresco’s proven ability to execute is
complemented by a cutting-edge brand strategy spearheaded by several of
the brightest minds in consumer marketing in the nation. Cresco’s
products are tailored to all major consumer segments: everyday cannabis,
medicinally focused, connoisseur grade, and chef inspired edibles by
James Beard Award-winning pastry chef Mindy Segal. Learn more about
Cresco Labs at www.crescolabs.com.
ABOUT ORIGIN HOUSE
Origin House is a growing cannabis brands and distribution company
operating across key markets in the U.S. and Canada, with a strategic
focus on becoming a preeminent global house of cannabis brands. Origin
House’s foundation is in California, the world’s largest regulated
cannabis market, where it delivers over 130 branded cannabis products
from 50+ brands to the majority of licensed dispensaries. Origin House’s
brand development platform is operated out of five licensed facilities
located across California, and provides distribution, manufacturing,
cultivation and marketing services for its brand partners. Origin House
is actively developing infrastructure to support the proliferation of
its brands internationally, initially through its acquisition of
Canadian retailer 180 Smoke. Origin House’s shares trade on the CSE
under the symbol “OH” and on the OTCQX under the symbol “ORHOF”. Origin
House is the registered business name of CannaRoyalty Corp. For more
information, visit www.originhouse.com.
FORWARD LOOKING STATEMENTS
This press release contains “forward-looking information” within the
meaning of applicable Canadian securities legislation and may also
contain statements that may constitute “forward-looking statements”
within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Such forward-looking
information and forward-looking statements are not representative of
historical facts or information or current condition, but instead
represent only Cresco Labs’ and/or Origin House’s beliefs regarding
future events, plans or objectives, many of which, by their nature, are
inherently uncertain and outside of the Cresco Labs’ and/or Origin
House’s control. Generally, such forward-looking information or
forward-looking statements can be identified by the use of
forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’
‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’
‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of
those forms or other comparable terms.
Forward looking statements are based on certain assumptions regarding
the Company and Origin House, including but not limited to expected
growth, results of operations, performance, industry trends and growth
opportunities. While the Company considers these assumptions to be
reasonable based on currently available information, they may prove to
be incorrect. By their nature, forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including but not limited to:
(i) risks associated with general economic conditions; (ii) adverse
industry events; (iii) future legislative and regulatory developments;
(iv) inability to access sufficient capital and/or inability to access
sufficient capital on favourable terms; (v) the evolving cannabis
industry in North America generally; (vi) the ability of the Company to
implement its business strategies; (viii) risks associated with currency
and interest rate fluctuations; (ix) risks discussed in public filings
relating to the Transaction, as well as those risks discussed under
“Risk Factors” in the Company’s CSE Listing Statement filed with SEDAR
or Origin House’s management’s discussion and analysis filed with SEDAR;
(x) and other factors, many of which are beyond the control of Cresco
Labs’ and/or Origin House.
Readers are cautioned that the foregoing list of factors is not
exhaustive. Because of these uncertainties, readers should not place
undue reliance on the forward-looking statements. No assurances are
given as to the future trading price or trading volumes of Cresco Labs’
Shares, or Origin House Shares, nor as to the Cresco Labs’ and/or Origin
House’s financial performance in future financial periods. Except to the
extent required by applicable laws, Cresco Labs’ and/or Origin House
does not intend to update any of these factors or any of the
forward-looking statements contained herein, whether as a result of new
information, future event or otherwise. Except as otherwise indicated,
this press release speaks as of the date hereof. The distribution of
this press release does not imply that there has been no change after
the date hereof or create any duty or commitment to update or supplement
any information provided in this press release or otherwise.
Jason Erkes, Cresco Labs
For general Cresco Labs inquiries:
LodeRock Advisors Inc., Origin House Investor
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.
The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.
The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.
Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer
DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.
Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.
“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”
Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028
- Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
- Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer
- Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028
- Solei Brand Launches New Cannabis Infused Cold Brew Teas
- Proton Capital Enters Into Agreement to Purchase PharmaChoice Canada Branded Pharmacy In Saskatoon For Proposed Qualifying Transaction
- Right on Brands Announces 11th Store Opening
- HYTN Broadens Reach with Innovative Cannabis-Infused Nano Shot
- Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024
- Global Macadamia Market to Surpass USD 3.42 billion by 2031 Driven by Growing Demand for Plant-based Food Products
- Cavitation Technologies, Inc. has Renewed a 3-year Agreement With Desmet Ballestra Group s.a. and Received a $650,000 Purchase Order
- EvenMix Brings Cutting-Edge Advantage of Its Mixing Technology to Muskoka Grown
- Hemp, Inc. Profiled in Latest Global Report
- CBD Nutraceuticals Market To Reach USD 16.9 Billion By 2032 Report By DataHorizzon Research
- Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
- TILT Holding’s Jupiter Research Introduces THREDZ, the Future of 510 Cartridges
Trending on Grassnews
Innocan2 weeks ago
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Cannabis2 weeks ago
Cavitation Technologies, Inc. has Renewed a 3-year Agreement With Desmet Ballestra Group s.a. and Received a $650,000 Purchase Order
Cannabis2 weeks ago
Hemp, Inc. Profiled in Latest Global Report
Cannabis2 weeks ago
CBD Nutraceuticals Market To Reach USD 16.9 Billion By 2032 Report By DataHorizzon Research
Cannabis2 weeks ago
EvenMix Brings Cutting-Edge Advantage of Its Mixing Technology to Muskoka Grown
Cannabis2 weeks ago
TILT Holding’s Jupiter Research Introduces THREDZ, the Future of 510 Cartridges
Cannabis1 week ago
Global Macadamia Market to Surpass USD 3.42 billion by 2031 Driven by Growing Demand for Plant-based Food Products
Cannabis7 days ago
HYTN Broadens Reach with Innovative Cannabis-Infused Nano Shot